CTRI/2022/05/042461进行中（未招募）未知
An Evaluation of the Pharmacokinetics and Tolerability of AV104 (Nalmefene hydrochloride) buccal films in Cholestatic Liver Disease Subjects.
Avior Bio Inc0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Subjects will be considered eligible for the study based on the following criteria:
- •1. Subjects willing and able to provide voluntary written informed consent and to follow the protocol requirements
- •2. Male or female subjects between 18 and 75 years of age (both inclusive) with body weight less than equal to 120 kg and BMI (Body Mass Index) within range of greater than 18.00 and less than 35.00 kg per m2
- •3. Cholestatic liver disease subjects with known history of persistent generalized pruritus for at least 4 weeks prior to screening
- •4. 12-lead ECG recording within normal or within acceptable limits or are of no clinical significance with respect to his or her participation in the study as confirmed by the investigator
- •5. Normal chest X-ray taken within one year before the day of dosing
- •6. Males, non-fecund females, or females of child-bearing potential, using an approved method of birth control (2 independent highly effective barrier methods of birth control) as per Appendix-A, willing to continue use of the acceptable methods of birth control throughout the study period
- •7. Female subjects with negative pregnancy test at the time of screening and baseline visit
- •8. No history of addiction to any recreational drug or drug dependence or alcohol addiction
排除标准
- •Subjects will be excluded from the study based on the following criteria:
- •1. Known hypersensitivity, allergy or intolerance to nalmefene or other μ-opioid receptor (MOR) antagonist or to any of the excipients of IP
- •2. History of substance use disorder as per the Diagnostic and Statistical Manual of Mental Disorders â?? 5th edition (DSM-5) criteria within 90 days prior to study entry
- •3. Subjects with positive urine test for opioid use (UDT)
- •4. Subjects with positive urine alcohol test
- •5. Subjects having any clinically significant abnormality of the buccal mucosa which could impact drug absorption
- •6. Use of an investigational drug within 30 days preceding this study
- •7. History or presence of hepatic decompensation (e.g. variceal bleeds, poorly controlled ascites, encephalopathy)
- •8. Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than five times the ULN
- •9. Subjects with SCr (Serum creatinine) greater than 2.5 mg per dL
- •10. Lactating women
- •11. Any other medical condition or reason that, in the opinion of the investigator or research physician, makes the subject unsuitable to participate in the clinical study
- •12. Subjects with positive serology for Human Immunodeficiency Virus (HIV) or positive test result for rapid plasma reagin (RPR)
- •13. Subjects with loss of greater than equal to 350 mL (1 unit) of blood within 90 days of enrolment in the study
- •14. Subjects with confirmed novel coronavirus infection (COVID-19) or subjects who have taken COVID-19 vaccine within 4 weeks prior to dosing
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64
进行中（未招募）
1 期
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioChronic Hepatitis B Virus (HBV) InfectionMedDRA version: 16.1 Level: LLT Classification code 10019743 Term: Hepatitis B virus (HBV) System Organ Class: 100000004848EUCTR2005-005816-26-GBBristol-Myers Squibb International Corporation64
进行中（未招募）
不适用
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioEUCTR2005-005816-26-Outside-EU/EEABristol-Myers Squibb International Corporation64
已完成
不适用
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy VolunteersKidney failure10038430chronic kidney diseaseNL-OMON36630Eli Lilly32
已完成
不适用
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy ParticipantsNL-OMON50998Eli Lilly16